公开(公告)号：US07166469B2

公开(公告)日：2007-01-23

申请号：US10174797

申请日：2002-06-18

申请人： Paul N. Holvoet ,  Désiré J. Collen

发明人： Paul N. Holvoet ,  Désiré J. Collen

IPC分类号： G01N33/92

CPC分类号： G01N33/721 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/324 ,  Y10S435/967 ,  Y10S435/973 ,  Y10S436/809 ,  Y10S436/819 ,  Y10T436/104165 ,  Y10T436/105831

摘要： A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams/deciliter.

摘要翻译： 公开了一种具有临床足够程度的诊断准确度的方法，其用于检测来自一般群体的人类患者中冠状动脉疾病的存在并区分该患者的疾病阶段。 这些阶段首先是非急性期，无论是无症状的冠状动脉疾病还是稳定型心绞痛，其次是称为不稳定性心绞痛的急性期，第三，称为急性心肌梗死的急性期。 疾病状态（与非患病状态相反）由来自患者的样品中的第一标记物的临床显着存在表示。 两个急性期之一，不稳定性心绞痛或急性心肌梗死的存在，由来自患者的样品中的第二标志物的临床显着存在表示。 称为急性心肌梗塞的更严重急性期的存在由来自患者的样品中第三个标志物的临床显着存在表示。 优选地，第一标记包含OxLDL，第二标记包含MDA修饰的LDL，第三标记是肌钙蛋白。 优选使用可以以低至0.02毫克/分升浓度的浓度检​​测未稀释的人血浆中那些标记物的存在的单克隆抗体来检测OxLDL和MDA修饰的LDL。

公开(公告)号：US07604952B2

公开(公告)日：2009-10-20

申请号：US11654097

申请日：2007-01-16

申请人： Paul N. Holvoet ,  Désiré J. Collen

发明人： Paul N. Holvoet ,  Désiré J. Collen

IPC分类号： G01N33/92

CPC分类号： G01N33/721 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/324 ,  Y10S435/967 ,  Y10S435/973 ,  Y10S436/809 ,  Y10S436/819 ,  Y10T436/104165 ,  Y10T436/105831

摘要： A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams/deciliter.

摘要翻译： 公开了一种具有临床足够程度的诊断准确度的方法，其用于检测来自一般群体的人类患者中冠状动脉疾病的存在并区分该患者的疾病阶段。 这些阶段首先是非急性期，无论是无症状的冠状动脉疾病还是稳定型心绞痛，其次是称为不稳定性心绞痛的急性期，第三，称为急性心肌梗死的急性期。 疾病状态（与非患病状态相反）由来自患者的样品中的第一标记物的临床显着存在表示。 两个急性期之一，不稳定性心绞痛或急性心肌梗死的存在，由来自患者的样品中的第二标志物的临床显着存在表示。 称为急性心肌梗塞的更严重急性期的存在由来自患者的样品中第三个标志物的临床显着存在表示。 优选地，第一标记包含OxLDL，第二标记包含MDA修饰的LDL，第三标记是肌钙蛋白。 优选使用可以以低至0.02毫克/分升浓度的浓度检​​测未稀释的人血浆中那些标记物的存在的单克隆抗体来检测OxLDL和MDA修饰的LDL。

公开(公告)号：US06309888B1

公开(公告)日：2001-10-30

申请号：US09148158

申请日：1998-09-04

申请人： Paul N. Holvoet ,  Désiré J. Collen

发明人： Paul N. Holvoet ,  Désiré J. Collen

IPC分类号： G01N3392

CPC分类号： G01N33/721 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/324 ,  Y10S435/967 ,  Y10S435/973 ,  Y10S436/809 ,  Y10S436/819 ,  Y10T436/104165 ,  Y10T436/105831

摘要： A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams/deciliter.

摘要翻译： 公开了一种具有临床足够程度的诊断准确度的方法，其用于检测来自一般群体的人类患者中冠状动脉疾病的存在并区分该患者的疾病阶段。 这些阶段首先是非急性期，无论是无症状的冠状动脉疾病还是稳定型心绞痛，其次是称为不稳定性心绞痛的急性期，第三，称为急性心肌梗死的急性期。 疾病状态（与非患病状态相反）由来自患者的样品中的第一标记物的临床显着存在表示。 两个急性期之一，不稳定性心绞痛或急性心肌梗死的存在，由来自患者的样品中的第二标志物的临床显着存在表示。 称为急性心肌梗塞的更严重急性期的存在由来自患者的样品中第三个标志物的临床显着存在表示。 优选地，第一标记包含OxLDL，第二标记包含MDA修饰的LDL，第三标记是肌钙蛋白。 优选使用可以以低至0.02毫克/分升浓度的浓度检​​测未稀释的人血浆中那些标记物的存在的单克隆抗体来检测OxLDL和MDA修饰的LDL。